Towards Healthcare
Oncology Clinical Trial Market to Lead USD 22.85 Bn by 2034

Oncology Clinical Trial Market Boosted by Immunotherapy and Precision

According to market projections, the oncology clinical trial sector is expected to grow from USD 13.64 billion in 2024 to USD 22.85 billion by 2034, reflecting a CAGR of 5.30%. Growing patient awareness, better diagnostic tools have increased the demand for the treatment, which has driven the growth of the market in the future. North America led the global market owing to the strong presence of leading pharmaceutical and biotechnology companies.

Content

  • Insight Code: 6134
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The oncology clinical trial market stands at USD 14.36 billion in 2025 and is expected to reach USD 22.85 billion by 2034, growing at a CAGR of 5.30% from 2024 to 2034.

North America is leading the oncology clinical trial market share 40% due to the growing demand for personalized medicines, increasing investments, and the presence of key players.

The oncology clinical trial market includes 7 segments including by phase, by study design, by cancer type, by therapy type, by sponsor, by end user, and by region.

Key trends include the adoption of inorganic growth strategies, government initiatives and Funding.

Digital health tools, decentralized trial platforms, AI-driven patient matching, ePROs, and remote monitoring are improving efficiency, patient engagement, and data accuracy in oncology trials.

International Agency for Research on Cancer (IARC), Personalized Medicine Coalition, Government of Canada, Indian Cancer Society, Cancer Aid and Research Foundation (CARF), Food and Drug Administration, clinicaltrials.gov, Cancer Patients Aid Association (CPAA), GOV.UK
Any Questions